Advertisement
Mr. Rackear joined NPS in July 2007 as associate general counsel.Previously, he was vice president and general counsel at Chugai Pharma, USAand vice president and general counsel at Amersham Biosciences Corp. Hereceived his law degree from New York University and is a member of the NewYork and New Jersey state bar associations.
Advertisement
Mr. Beshar is a former CFO of various public and private companies and hasmore than twenty five years of general and financial management experience.Most recently, he served as executive vice president and chief financialofficer of Cambrex Corporation, a global life sciences company. He was alsosenior vice president and chief financial officer at Dendrite International, aleading provider of services to the life sciences industry. Mr. Beshar beganhis career with Arthur Andersen & Co. He is a certified public accountant,obtained his undergraduate degree in accounting and finance from MichiganState University and is a graduate of The Executive Program at the DardenGraduate School of Business, University of Virginia.
NPS president and CEO, Dr. Tony Coles, stated: "I congratulate Andy on hispromotion and extend a warm welcome to Luke, who brings great financial andgeneral management experience to NPS. I also wish to acknowledge thecontributions of Val and Gerry, who played key roles in restructuring NPS sothat the company could continue to develop its late-stage product candidatesand pursue its mission of treating diseases and transforming lives. I amgrateful for their guidance and counsel and thank them for their willingnessto ensure a smooth transition of responsibilities to their successors. Valand Gerry have both been creative and effective forces in the life of thecompany and we wish them great success in their next endeavors. Gerry, inparticular, has also done a great job strengthening the company's balancesheet this year through a series of innovative financings which have enabledus to retire our 2008 convertible debt."
About NPS
NPS Pharmaceuticals is a biopharmaceutical company focused on thedevelopment and commercialization of small molecules and recombinant proteinsas drugs, primarily for the treatment of metabolic, bone and mineral, andcentral nervous system disorders. The company has drug candidates in variousstages of clinical development. Additional information is available on thecompany's website, http://www.npsp.com.
Note: Statements made in this press release, which are not historical innature, constitute forward-looking statements for purposes of the safe harborprovided by the Private Securities Litigation Reform Act of 1995. Thesestatements are based on management's current expectations and beliefs and aresubject to a number of factors and uncertainties that could cause actualresults to differ materially from those described in the forward-lookingstatements. All information in this press release is as of November 13, 2007and we undertake no duty to update this information. A more completedescription of these risks can be found in our filings with the Securities andExchange Commission, including our Annual Report on Form 10-K for theyear-ended December 31, 2006 and our Quarterly Report on Form
